This segment focuses on the development and commercialization of blood-based tests, including Nodify XL2 and Nodify CDT, designed to assess the risk of malignancy in patients with suspicious lung nodules. These tests aid physicians in reclassifying the risk and determining the appropriate treatment pathway. Research and development efforts are directed towards improving the accuracy and predictive power of these tests through advanced data analytics and biomarker discovery. The goal is to reduce unnecessary invasive procedures, improve patient outcomes, and lower healthcare costs. Future opportunities include expanding the clinical utility of Nodify tests and integrating them into comprehensive lung cancer screening programs. Partnerships with pulmonary advanced practice providers are crucial for delivering medical education and promoting the adoption of these innovative diagnostic tools.

This segment is dedicated to developing and offering diagnostic tests, such as GeneStrat ddPCR, VeriStrat, and GeneStrat NGS, that measure mutations in tumors and assess the patient's immune system to establish prognosis and guide treatment decisions in lung cancer. Research and development activities focus on identifying novel biomarkers and refining testing methodologies to enhance the precision and effectiveness of treatment selection. The segment aims to improve patient survival rates and quality of life by providing clinicians with actionable insights for personalized treatment strategies. Future growth potential lies in expanding the application of these tests to other cancer types and integrating them with emerging therapeutic modalities. Collaborations with biopharmaceutical companies are essential for developing companion diagnostics and accelerating the adoption of personalized medicine in oncology.

This segment provides diagnostic and clinical research services to biopharmaceutical companies, including clinical trial testing. Biodesix leverages its expertise in biomarker discovery, assay development, and data analytics to support the development of new therapies and improve clinical trial outcomes. Research and development efforts are focused on developing innovative diagnostic tools and methodologies that can be used to identify patient populations most likely to benefit from specific treatments. The segment aims to accelerate the development of new therapies and improve patient access to personalized medicine. Future opportunities include expanding the range of services offered and establishing strategic partnerships with leading biopharmaceutical companies. Regulatory compliance and adherence to quality standards are critical aspects of this segment.